This 6-week Prospective, Randomized, Open-label Blinded End point (PROBE) study
conducted at 12 sites in the United States compared the efficacy and safety of atorvastatin …

Background Despite the demonstrated benefits of low-density lipoprotein cholesterol (LDL-
C) reduction in reducing the risk of coronary heart disease, many patients receiving lipid …

PURPOSE: To evaluate the efficacy of lovastatin in African Americans (AA) diagnosed with
primary hypercholesterolemia. PATIENTS AND METHODS: Forty-seven AA patients from the …

The objective of this multicenter, randomized, open-label, parallel-group, 8-week study was
to evaluate the comparative dose efficacy of the 3-hydroxy-3-methylglutaryl coenzyme A …

A large-scale epidemiological study showed clinically that hyperlipidemia is one of the major
risk factors for atherosclerosis and coronary heart disease1). In addition, various large-scale …

In this 2-year study, 787 patients with hypercholesterolemia received either atorvastatin 10
mg to 80 mg/day (623 patients) or lovastatin 20 mg to 80 mg/day (164 patients). Patients …

This 1-year, double-blind, active-controlled, multicenter study compared the efficacy and
safety of atorvastatin to pravastatin and evaluated their ability to achieve target low-density …

Reduction in plasma lipids has been recognized as one of the primary cardiovascular risk
reduction strategies in the secondary prevention of coronary heart disease (CHD). The …

Background Statins have been known to reduce progression of atherosclerosis when used
in high dosage in patients with elevated cholesterol. A large majority of Indian patients …

Background: High levels of total and LDL-cholesterol are associated with an increased risk
of atherosclerotic vascular disease. Lowering of serum cholesterol levels by pharmacologic …